 In 2019, Professor Kerstin Noëlle Vokinger and Dr. Urs Jakob Mühlematter, two researchers at the University of Zurich, analyzed cases of the Federal Supreme Court of Switzerland to assess which pharmaceutical companies and which medical drugs were involved in legal actions against the Federal Office of Public Health (FOPH) regarding pricing decisions of medical drugs.In general, involved private parties (such as pharmaceutical companies) and information that would reveal the private party (for example, drug names) are anonymized in Swiss judgments.The researchers were able to re-identify 84% of the relevant anonymized cases of the Federal Supreme Court of Switzerland by linking information from publicly accessible databases.